Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Araki, Yoshio ^a,b   Yoshikawa, Kazuhiro ^b,c   Okamoto, Sho ^a   Sumitomo, Masaki ^a   Maruwaka, Mikio ^a   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN; BETA DEFENSIN 133; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; LIVER EXPRESSED ANTIMICROBIAL PEPTIDE 2; OXYNTOMODULIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROENKEPHALIN; PROENKEPHALIN A; PROTEIN; UNCLASSIFIED DRUG; UROCORTIN II; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANION EXCHANGE; ARTICLE; BRAIN ANGIOGRAPHY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; INFANT; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MOYAMOYA DISEASE; PATHOGENESIS; PILOT STUDY; PREDICTION; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; CEREBROSPINAL FLUID; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; PROTEOMICS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MOYAMOYA DISEASE; PILOT PROJECTS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78049485888     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-112     Document Type: Article

References (39)

1. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969, 20:288-299.
2. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, Kojima M, Lin Y, Ohno Y. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 1997, 99(Suppl):S1-S5. 10.1016/S0303-8467(97)00031-0, 9409395.
3. Goto Y, Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 1992, 32:883-886. 10.2176/nmc.32.883, 1282678.
4. Mineharu Y, Takenaka K, Yamakawa H, Inoue K, Ikeda H, Kikuta KI, Takagi Y, Nozaki K, Hashimoto N, Koizumi A. Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry 2006, 77:1025-1029. 10.1136/jnnp.2006.096040, 2077755, 16788009.
5. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 1999, 64:533-537. 10.1086/302243, 1377762, 9973290.
6. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, Arinami T. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 2004, 49:278-281. 10.1007/s10038-004-0143-6, 15362573.
7. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 2000, 15:179-182. 10.1177/088307380001500307, 10757474.
8. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 2000, 31:930-935.
9. Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 1993, 24:1960-1967.
10. Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya disease. Stroke 1983, 14:50-58.
11. Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, Matsuura N, Ishizaki R, Kikuchi H, Hashimoto N. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 1998, 89:623-629. 10.3171/jns.1998.89.4.0623, 9761057.
12. Malek AM, Connors S, Robertson RL, Folkman J, Scott RM. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 1997, 27:182-189. 10.1159/000121249, 9577971.
13. Nanba R, Kuroda S, Ishikawa T, Houkin K, Iwasaki Y. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 2004, 35:2837-2842. 10.1161/01.STR.0000148237.13659.e6, 15528455.
14. Takagi Y, Kikuta K, Nozaki K, Fujimoto M, Hayashi J, Imamura H, Hashimoto N. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease. Neurosurgery 2007, 60:338-345. 10.1227/01.NEU.0000249275.87310.FF, 17290185.
15. Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke 1996, 27:2160-2165.
16. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967. 10.1126/science.275.5302.964, 9020076.
17. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005, 15:57-63. 10.1016/j.tcm.2005.02.002, 15885571.
18. Fuse T, Takagi T, Fukushima T, Hashimoto N, Yamada K. Arteriovenous malformation associated with moyamoya disease. Childs Nerv Syst 1996, 12:404-408. 10.1007/BF00395095, 8869778.
19. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007, 6:25. 10.1186/1476-4598-6-25, 1852117, 17407558.
20. Cho WC, Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 2007, 4:401-410. 10.1586/14789450.4.3.401, 17552924.
21. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, Ampt K, Stingl C, Dane A, Muilwijk B, Luitwieler RL, Smitt PA, Hintzen RQ, Bischoff R, Wijmenga SS, Hankemeier T, van GA, Luider TM. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics 2010, 9:2063-2075. 10.1074/mcp.M900877-MCP200, 20811074.
22. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002, 292:587-592. 10.1006/bbrc.2002.6678, 11922607.
23. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 2008, 29:961-968. 10.1016/j.neurobiolaging.2007.01.011, 17321007.
24. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH, Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005, 95:1461-1471. 10.1111/j.1471-4159.2005.03478.x, 1540444, 16313519.
25. Research on intractable diseases of the Ministry of Health, Labour and Welfare, Japan Recommendations for the Management of Moyamoya Disease: A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease). Surg Cereb Stroke 2009, 37:321-337. (in Japanese), Research on intractable diseases of the Ministry of Health, Labour and Welfare, Japan.
26. Kojima T, Yoshikawa K, Saga S, Yamada T, Kure S, Matsui T, Uemura T, Fujimitsu Y, Sakakibara M, Kodera Y, Kojima H. Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins. J Surg Res 2009, 155:13-17. 10.1016/j.jss.2008.07.024, 19394641.
27. Su Y, Shen J, Qian H, Ma H, Ji J, Ma H, Ma L, Zhang W, Meng L, Li Z, Wu J, Jin G, Zhang J, Shou C. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 2007, 98:37-43. 10.1111/j.1349-7006.2006.00339.x, 17052262.
28. Gianola D, Perez-Enciso M, Toro MA. On marker-assisted prediction of genetic value: beyond the ridge. Genetics 2003, 163:347-365. 1462425, 12586721.
29. Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO, Tsubouchi H. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 2007, 45:948-956. 10.1002/hep.21598, 17393466.
30. Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology 2006, 44:658-666. 10.1002/hep.21294, 16941699.
31. Braun KP, Bulder MM, Chabrier S, Kirkham FJ, Uiterwaal CS, Tardieu M, Sebire G. The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain 2009, 132:544-557. 10.1093/brain/awn313, 2640213, 19039009.
32. Sebire G. Transient cerebral arteriopathy in childhood. Lancet 2006, 368:8-10. 10.1016/S0140-6736(06)68944-7, 16815360.
33. Kim SK, Yoo JI, Cho BK, Hong SJ, Kim YK, Moon JA, Kim JH, Chung YN, Wang KC. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke 2003, 34:2835-2841. 10.1161/01.STR.0000100159.43123.D7, 14605320.
34. Cho WC. Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 2007, 5:77-85. 10.1016/S1672-0229(07)60018-7, 17893073.
35. Rohlff C, Southan C. Proteomic approaches to central nervous system disorders. Curr Opin Mol Ther 2002, 4:251-258.
36. Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003, 62:855-862.
37. Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, Zhang J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 2007, 7:469-473. 10.1002/pmic.200600756, 17211832.
38. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005, 2:57-70. 10.1586/14789450.2.1.57, 15966853.
39. Cho WC. Research progress in SELDI-TOF MS and its clinical applications. Sheng Wu Gong Cheng Xue Bao 2006, 22:871-876.